
ESMO 2019: Dr. Mirza on Important Trials with PARP Inhibitors in Ovarian Cancer
Episodes in this series

Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology in Rigshospitalet, Copenhagen University Hospital, discusses data presented with PARP inhibitors in ovarian cancer at the 2019 ESMO Congress.
PARP inhibitors have become standard of care as frontline maintenance therapy in ovarian cancer, says Mirza. Data from 3 positive trials have shown the benefit of using PARP inhibitors in this new paradigm, he says.
Data from the
Data from the
Though, the median PFS benefit was more pronounced in patients with BRCA mutations (HR, 0.40; 95% CI, 0.27-0.62; P < 0.001) versus the overall population (HR, 0.62; 95% CI, 0.50-0.75; P <.001).
The decision of which drug to use has to be taken on an individualized basis, says Mirza.
Finally, data from the
VELIA marks the first randomized trial exploring platinum-based chemotherapy plus a PARP inhibitor. The combination is thought to have a synergistic effect whereby chemotherapy damages circulating tumor DNA and PARP blocks cell repair, says Mirza.
Going forward, Mirza is hopeful that ongoing research will lead to treatments with fewer adverse events and longer remissions.
Related to this article



















